Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content [Randomisierte, placebokontrollierte, klinische Crossover Studie um den Effekt von Dapagliflozin auf die mikrovaskuläre und makrovasculäre Zirkulation und den Natriumgehalt des Körpers zu analysieren.]

Trial Profile

Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content [Randomisierte, placebokontrollierte, klinische Crossover Studie um den Effekt von Dapagliflozin auf die mikrovaskuläre und makrovasculäre Zirkulation und den Natriumgehalt des Körpers zu analysieren.]

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Diabetic retinopathy; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Oct 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top